Thu, Jan 29, 2015, 5:06 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • levonchiko levonchiko May 22, 2013 6:14 PM Flag

    Increasing price target to $18-positive data likely

    Additional upside in NTM YE:reiterate out perform.
    We are increasing our price target on Insm to $18/share ahead of an upcoming positive,readout from their phase III trial of Arikace in CF (PA) lung line Arikace data in CF is expected in late June/ July and is to be followed by data on NTM by YE:13

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If you read how these analysts are calculating the share price a few things stand out. First, they project a 40% tax rate - which will never happen. 2/3 of sales will be overseas and tax rates in Great Britain or Ireland range from 15% to 8%. The average effective tax rate will likely be more like 20%. Second, they are discounting at a rate of 25% per year - at the very high end of the scale - to get a net present value. They also don't seem to take into consideration the tax loss carry forward and assign no value to Iplex. Finally, the value on a buyout from big farma, given their even lower effective tax rates and a much more favorable net present value, would likely end up 2x to 3x higher than the adjusted value.

      Sentiment: Buy

    • Levonchiko, could you please clarify something for me? This $18 target it by any chance "pre-split" price?


15.96+0.70(+4.59%)Jan 29 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.